Drug discovery and development for neglected diseases: The DNDi model

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 175-181

  Chatelain, Eric ^a   Ioset, Jean Robert ^a  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

Chagas disease; Human african trypanosomiasis; Lead optimization; Leishmaniasis; Product development partnerships; R D; Screening

Indexed keywords

DRUG DEVELOPMENT; DRUG RESEARCH; DRUG SCREENING; DRUGS FOR NEGLECTED DISEASES INITIATIVE; HEALTH CARE DISTRIBUTION; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; NEGLECTED DISEASE; REVIEW; ECONOMICS; HUMAN; METHODOLOGY; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PUBLIC-PRIVATE PARTNERSHIP; TRYPANOSOMATID INFECTION;

DRUG DISCOVERY; EUGLENOZOA INFECTIONS; HUMANS; MODELS, ORGANIZATIONAL; NEGLECTED DISEASES; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 79952967329     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S16381     Document Type: Review

References (20)

1. Feasey N, Wansbrough-Jones M, Mabey DC, Solomon AW. Neglected tropical diseases. Br Med Bull. 2010;93:179-200.
2. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis. 2009;3:e412.
3. Hotez PJ, Pécoul B. "Manifesto" for advancing the control and elimination of neglected tropical diseases. PLoS Negl Trop Dis. 2010; 4:e718.
4. World Health Organization. http://www.who.int/topics/tropical_diseases/en/. Accessed December 6, 2010.
5. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet. 2010;375:239-247.
6. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis. 2007;1:e114.
7. Chirac P, Torreele E. Proportion of new drugs developed over the period from 1975 to 2004 that were for neglected tropical diseases and tuberculosis. Lancet. 2006;12:1560-561.
8. World Health Organization/Industry Drug Development Working Group. http://www.who.int/intellectualproperty/documents/en/IFPMA.pdf. Accessed December 6, 2010.
9. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2:e309.
10. Nwaka S, Ridley RG. Virtual deug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Disc. 2003;2:919-928.
11. Croft SL. Public-private partnership: from there to here. Trans R Soc Trop Med Hyg. 2005;99 Suppl 1:S9-S14.
12. The George Institute for International Health. G-FINDER: "Global Funding of Innovation for Neglected Disease" survey. Available from: http://www.thegeorgeinstitute.com. Accessed November 15, 2010.
13. Moran M, Guzman J, Ropars AL, et al. Neglected disease research and development: how much are we really spending? PLoS Med. 2009;6: e1000030.
14. Pécoul B. New drugs for neglected diseases: from pipeline to patients. PLoS Med. 2004;1:e6.
15. Torreele E, Bourdin B, Tweats D, et al. Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4(12):e923.
16. Preziosi P. Attrition rate R&D of pharmaceutical drugs. Nat Rev Drug Disc. 2004;3:521-526.
17. Woosley RL, Cossman J. Drug development and the FDA's critical path initiative. Clin Pharmacol Rev. 2007;81:129-133.
18. Don R, Chatelain E. Drug discovery for neglected diseases: view of a public-private partnership. In: Selzer PM, editor. Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates. Weinheim, Germany: Wiley-VCH GmbH &Co. KGaA; 2009: 33-43.
19. Curry S, Brown R. The target product profile as a planning tool in drug discovery research. Pharmatech. 2003:67-71.
20. Nwaka S, Ramirez B, Brun R, et al. Advancing drug innovation for neglected disease - criteria for lead progression. PLoS Negl Trop Dis. 2009;3:e440.